{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:57:36Z","timestamp":1790312256379,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T00:00:00Z","timestamp":1583539200000},"content-version":"am","delay-in-days":250,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.nbd.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T12:45:45Z","timestamp":1551789945000},"page":"163-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Systemic peptide mediated delivery of an siRNA targeting \u03b1-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-1941","authenticated-orcid":false,"given":"Brian","family":"Spencer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Rockenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jazmin","family":"Florio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Adame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar M.A.","family":"El-Agnaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyoun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Masliah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2019.03.001_bb0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte-endothelial interactions at the blood-brain barrier","volume":"7","author":"Abbott","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0010","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","article-title":"Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system","volume":"25","author":"Abeliovich","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2019.03.001_bb0015","first-page":"339","article-title":"Alpha-synucleinopathies","volume":"145","author":"Alafuzoff","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0020","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2017.11.015","article-title":"Selective alpha-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for Parkinson's disease","volume":"26","author":"Alarcon-Aris","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2019.03.001_bb0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1089\/hum.2016.017","article-title":"Gene therapy strategies for Alzheimer's disease: an overview","volume":"27","author":"Alves","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.nbd.2019.03.001_bb0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2202-14-6","article-title":"Time course and progression of wild type alpha-synuclein accumulation in a transgenic mouse model","volume":"14","author":"Amschl","year":"2013","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0035","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/nar\/gkj439","article-title":"Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging","volume":"34","author":"Bartlett","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.nbd.2019.03.001_bb0040","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2174\/1381612043384844","article-title":"ABC transporters and the blood-brain barrier","volume":"10","author":"Begley","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.nbd.2019.03.001_bb0045","first-page":"39","article-title":"Structural and functional aspects of the blood-brain barrier","volume":"61","author":"Begley","year":"2003","journal-title":"Prog. Drug Res."},{"key":"10.1016\/j.nbd.2019.03.001_bb0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnmol.2018.00036","article-title":"Silencing alpha synuclein in mature Nigral neurons results in rapid neuroinflammation and subsequent toxicity","volume":"11","author":"Benskey","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0055","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0169-409X(00)00139-3","article-title":"Delivery of peptides and proteins through the blood-brain barrier","volume":"46","author":"Bickel","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.nbd.2019.03.001_bb0060","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/mds.26028","article-title":"Down-regulating alpha-synuclein for treating synucleopathies","volume":"29","author":"Bourdenx","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2019.03.001_bb0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrn3887","article-title":"Spreading of pathology in neurodegenerative diseases: a focus on human studies","volume":"16","author":"Brettschneider","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00418-002-0475-2","article-title":"Multiple nicotinic acetylcholine receptor alpha-subunits are expressed in the arterial system of the rat","volume":"118","author":"Bruggmann","year":"2002","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0075","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0024-3205(03)00067-5","article-title":"Rat arteries contain multiple nicotinic acetylcholine receptor alpha-subunits","volume":"72","author":"Bruggmann","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0080","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1523\/JNEUROSCI.22-20-08797.2002","article-title":"Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein","volume":"22","author":"Cabin","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0085","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-007-0237-2","article-title":"Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration","volume":"114","author":"Cairns","year":"2007","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0090","doi-asserted-by":"crossref","first-page":"14966","DOI":"10.1073\/pnas.0406283101","article-title":"Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions","volume":"101","author":"Chandra","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2019.03.001_bb0095","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ymthe.2018.02.029","article-title":"Targeting amyloid-beta precursor protein, APP, splicing with antisense oligonucleotides reduces toxic amyloid-beta production","volume":"26","author":"Chang","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2019.03.001_bb0100","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1007592720793","article-title":"Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor","volume":"17","author":"Coloma","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.nbd.2019.03.001_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009313","article-title":"Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy","volume":"5","author":"Crews","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.03.001_bb0110","first-page":"166","article-title":"Alzheimer disease: antisense oligonucleotide reverses tau pathology","volume":"16","author":"Crunkhorn","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.nbd.2019.03.001_bb0115","doi-asserted-by":"crossref","first-page":"14524","DOI":"10.1073\/pnas.172514599","article-title":"Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP","volume":"99","author":"Dauer","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2019.03.001_bb0120","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The cellular phase of Alzheimer's disease","volume":"164","author":"De Strooper","year":"2016","journal-title":"Cell."},{"key":"10.1016\/j.nbd.2019.03.001_bb0125","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.neuron.2017.05.001","article-title":"Tau at the crossroads between neurotoxicity and neuroprotection","volume":"94","author":"DeVos","year":"2017","journal-title":"Neuron."},{"key":"10.1016\/j.nbd.2019.03.001_bb0130","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ajmg.a.38494","article-title":"Therapy development in Huntington disease: from current strategies to emerging opportunities","volume":"176","author":"Dickey","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.nbd.2019.03.001_bb0135","doi-asserted-by":"crossref","first-page":"12726","DOI":"10.1074\/jbc.M109.086827","article-title":"Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153","volume":"285","author":"Doxakis","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.03.001_bb0140","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.neuro.2004.05.002","article-title":"Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration","volume":"25","author":"Drolet","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.nbd.2019.03.001_bb0145","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0026-0495(98)90007-5","article-title":"Human blood-brain barrier insulin-like growth factor receptor","volume":"37","author":"Duffy","year":"1988","journal-title":"Metabolism"},{"key":"10.1016\/j.nbd.2019.03.001_bb0150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nbd.2017.05.002","article-title":"Differential effects of immunotherapy with antibodies targeting alpha-synuclein oligomers and fibrils in a transgenic model of synucleinopathy","volume":"104","author":"El-Agnaf","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.03.001_bb0155","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1515\/CCLM.2011.077","article-title":"alpha-synuclein in Parkinson disease and other neurodegenerative disorders","volume":"49","author":"Eller","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.nbd.2019.03.001_bb0160","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1038\/s41598-017-04232-4","article-title":"Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson's disease","volume":"7","author":"Fang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2019.03.001_bb0165","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1073\/pnas.88.11.4771","article-title":"Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier","volume":"88","author":"Friden","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2019.03.001_bb0170","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/s41593-018-0221-2","article-title":"Selective vulnerability in neurodegenerative diseases","volume":"21","author":"Fu","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0175","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13195-017-0307-1","article-title":"Gene suppression approaches to neurodegeneration","volume":"9","author":"Ghosh","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2019.03.001_bb0180","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/jamaneurol.2018.2505","article-title":"Mechanisms of cell-to-cell transmission of pathological tau: a review","volume":"76","author":"Gibbons","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0185","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1016\/j.febslet.2005.08.079","article-title":"Dicing and slicing: the core machinery of the RNA interference pathway","volume":"579","author":"Hammond","year":"2005","journal-title":"FEBS Lett."},{"key":"10.1016\/j.nbd.2019.03.001_bb0190","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fnagi.2014.00213","article-title":"Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease","volume":"6","author":"Isaias","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0195","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0896-6273(95)90302-X","article-title":"The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system","volume":"14","author":"Iwai","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2019.03.001_bb0200","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/mt.2015.232","article-title":"Development of nonviral vectors targeting the brain as a therapeutic approach for Parkinson's disease and other brain disorders","volume":"24","author":"Javed","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2019.03.001_bb0205","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","article-title":"Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases","volume":"21","author":"Jucker","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0210","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1074\/jbc.M309219200","article-title":"BACE1 suppression by RNA interference in primary cortical neurons","volume":"279","author":"Kao","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.03.001_bb0215","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1093\/hmg\/ddv442","article-title":"Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia","volume":"25","author":"Keiser","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.03.001_bb0220","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainres.2014.01.010","article-title":"Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects","volume":"1550","author":"Khodr","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2019.03.001_bb0225","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/323734a0","article-title":"Complete protein sequence and identification of structural domains of human apolipoprotein B","volume":"323","author":"Knott","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2019.03.001_bb0230","doi-asserted-by":"crossref","first-page":"30451","DOI":"10.1016\/S0021-9258(18)43834-3","article-title":"Induction of cholinergic differentiation with neurite sprouting by de novo biosynthesis and expression of GD3 and b-series gangliosides in Neuro2a cells","volume":"269","author":"Kojima","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.03.001_bb0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-211-73574-9_7","article-title":"The therapeutic potential of siRNA in gene therapy of neurodegenerative disorders","author":"Koutsilieri","year":"2007","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.nbd.2019.03.001_bb0240","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/WCO.0000000000000579","article-title":"Update in therapeutic strategies for Parkinson's disease","volume":"31","author":"Kulisevsky","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0245","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev-pharmtox-010814-124852","article-title":"Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier","volume":"55","author":"Lajoie","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0250","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of alpha-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0255","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1261\/rna.5239604","article-title":"In vivo activity of nuclease-resistant siRNAs","volume":"10","author":"Layzer","year":"2004","journal-title":"RNA"},{"key":"10.1016\/j.nbd.2019.03.001_bb0260","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3121","article-title":"Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration","volume":"13","author":"Lee","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0265","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.neures.2011.05.008","article-title":"Protein aggregate spreading in neurodegenerative diseases: problems and perspectives","volume":"70","author":"Lee","year":"2011","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.nbd.2019.03.001_bb0270","doi-asserted-by":"crossref","first-page":"10949","DOI":"10.1021\/bi00109a020","article-title":"Structure-function relationships of curaremimetic neurotoxin loop 2 and of a structurally similar segment of rabies virus glycoprotein in their interaction with the nicotinic acetylcholine receptor","volume":"30","author":"Lentz","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.nbd.2019.03.001_bb0275","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1326-3-19","article-title":"In vivo silencing of alpha-synuclein using naked siRNA","volume":"3","author":"Lewis","year":"2008","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2019.03.001_bb0280","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cmet.2013.04.002","article-title":"Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL","volume":"17","author":"Lim","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.nbd.2019.03.001_bb0285","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.nbd.2019.03.001_bb0290","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12264-008-0096-4","article-title":"RNA interference mediated silencing of alpha-synuclein in MN9D cells and its effects on cell viability","volume":"24","author":"Liu","year":"2008","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.nbd.2019.03.001_bb0295","article-title":"Trans-synaptic spread of tau pathology in vivo","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.03.001_bb0300","first-page":"1613","article-title":"Down-regulation amyloid beta-protein 42 production by interfering with transcript of presenilin 1 gene with siRNA","volume":"25","author":"Luo","year":"2004","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.nbd.2019.03.001_bb0305","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.brainres.2014.04.005","article-title":"Oligonucleotide-based therapy for neurodegenerative diseases","volume":"1584","author":"Magen","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2019.03.001_bb0310","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fncel.2014.00218","article-title":"Proteostasis in striatal cells and selective neurodegeneration in Huntington's disease","volume":"8","author":"Margulis","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0315","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/978-1-4939-2806-4_21","article-title":"Applications of ApoB LDLR-binding domain approach for the development of CNS-penetrating peptides for Alzheimer's disease","volume":"1324","author":"Masliah","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0320","series-title":"Cell-Penetrating Peptides","first-page":"331","article-title":"Applications of ApoB LDLR-binding domain approach for the development of CNS-penetrating peptides for Alzheimer's disease","author":"Masliah","year":"2015"},{"key":"10.1016\/j.nbd.2019.03.001_bb0325","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.03.001_bb0330","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.nbd.2019.03.001_bb0335","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-2094-10-4","article-title":"A quantitative spatiotemporal analysis of microglia morphology during ischemic stroke and reperfusion","volume":"10","author":"Morrison","year":"2013","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.nbd.2019.03.001_bb0340","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006338","article-title":"Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction","volume":"2","author":"Mucke","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.nbd.2019.03.001_bb0345","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1326-9-18","article-title":"Hippocampal neuronal cells that accumulate alpha-synuclein fragments are more vulnerable to Abeta oligomer toxicity via mGluR5--implications for dementia with Lewy bodies","volume":"9","author":"Overk","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2019.03.001_bb0350","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/14712598.2016.1230195","article-title":"Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies","volume":"16","author":"Pardridge","year":"2016","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.nbd.2019.03.001_bb0355","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40259-017-0248-z","article-title":"Delivery of biologics across the blood-brain barrier with molecular Trojan horse technology","volume":"31","author":"Pardridge","year":"2017","journal-title":"BioDrugs."},{"key":"10.1016\/j.nbd.2019.03.001_bb0360","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1023\/A:1016244500596","article-title":"Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate","volume":"12","author":"Pardridge","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.nbd.2019.03.001_bb0365","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1471-4159.2004.02378.x","article-title":"Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha\/gamma-synuclein null mutant mice","volume":"89","author":"Robertson","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2019.03.001_bb0370","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jnr.10231","article-title":"Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters","volume":"68","author":"Rockenstein","year":"2002","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.nbd.2019.03.001_bb0375","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.expneurol.2005.12.024","article-title":"Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi","volume":"198","author":"Sapru","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0380","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0306-4522(03)00036-8","article-title":"Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice","volume":"118","author":"Schluter","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2019.03.001_bb0385","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron."},{"key":"10.1016\/j.nbd.2019.03.001_bb0390","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.nbd.2019.03.001_bb0395","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nn1531","article-title":"Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model","volume":"8","author":"Singer","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0400","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2019.03.001_bb0405","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1073\/pnas.0702170104","article-title":"Targeted delivery of proteins across the blood-brain barrier","volume":"104","author":"Spencer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2019.03.001_bb0410","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1523\/JNEUROSCI.4390-09.2009","article-title":"Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases","volume":"29","author":"Spencer","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016575","article-title":"Peripheral delivery of a CNS targeted, metalo-protease reduces abeta toxicity in a mouse model of Alzheimer's disease","volume":"6","author":"Spencer","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.03.001_bb0420","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/mt.2012.66","article-title":"Lentivirus mediated delivery of neurosin promotes clearance of wild-type alpha-synuclein and reduces the pathology in an alpha-synuclein model of LBD","volume":"21","author":"Spencer","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2019.03.001_bb0425","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/mt.2014.129","article-title":"ESCRT-mediated uptake and degradation of brain-targeted alpha-synuclein single chain antibody attenuates neuronal degeneration in vivo","volume":"22","author":"Spencer","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2019.03.001_bb0430","doi-asserted-by":"crossref","first-page":"17917","DOI":"10.1074\/jbc.M114.557439","article-title":"A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis","volume":"289","author":"Spencer","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.03.001_bb0435","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-015-0043-6","article-title":"A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy","volume":"10","author":"Spencer","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2019.03.001_bb0440","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1523\/JNEUROSCI.0775-16.2016","article-title":"Reducing endogenous alpha-synuclein mitigates the degeneration of selective neuronal populations in an Alzheimer's disease transgenic mouse model","volume":"36","author":"Spencer","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0445","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/hmg\/ddv633","article-title":"Alpha-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease","volume":"25","author":"Spencer","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.03.001_bb0450","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1074\/jbc.M115.678185","article-title":"Systemic central nervous system (CNS)-targeted delivery of neuropeptide Y (NPY) reduces neurodegeneration and increases neural precursor cell proliferation in a mouse model of Alzheimer disease","volume":"291","author":"Spencer","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.03.001_bb0455","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acn3.321","article-title":"A-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease","volume":"3","author":"Spencer","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0460","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00401-018-1869-0","article-title":"Selective targeting of 3 repeat tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders","volume":"136","author":"Spencer","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0465","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-approved oligonucleotide therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2019.03.001_bb0470","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/jnr.20850","article-title":"Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C\/IP3 pathway and modulate the cell activation toward a neuroprotective role","volume":"83","author":"Suzuki","year":"2006","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.nbd.2019.03.001_bb0475","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4103\/1673-5374.133146","article-title":"Protective effect of alpha-synuclein knockdown on methamphetamine-induced neurotoxicity in dopaminergic neurons","volume":"9","author":"Tai","year":"2014","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.nbd.2019.03.001_bb0480","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.14","article-title":"Normalization of overexpressed alpha-Synuclein causing Parkinson's disease by a moderate gene silencing with RNA interference","volume":"4","author":"Takahashi","year":"2015","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"10.1016\/j.nbd.2019.03.001_bb0485","article-title":"LRP-1-mediated intracellular antibody delivery to the central nervous system","volume":"5","author":"Tian","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2019.03.001_bb0490","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1523\/JNEUROSCI.0567-10.2010","article-title":"Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors","volume":"30","author":"Ubhi","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0495","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2013.01.013","article-title":"Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies","volume":"138","author":"Valera","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.nbd.2019.03.001_bb0500","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jnc.13529","article-title":"Therapeutic approaches in Parkinson's disease and related disorders","volume":"139","author":"Valera","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2019.03.001_bb0505","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/nan.12312","article-title":"Review: novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy","volume":"42","author":"Valera","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0510","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","article-title":"Immunotherapeutic approaches targeting amyloid-beta, alpha-synuclein, and tau for the treatment of neurodegenerative disorders","volume":"13","author":"Valera","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nbd.2019.03.001_bb0515","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fnmol.2017.00329","article-title":"MicroRNA-101 modulates autophagy and oligodendroglial alpha-Synuclein accumulation in multiple system atrophy","volume":"10","author":"Valera","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.nbd.2019.03.001_bb0520","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1194653","article-title":"Tau reduction prevents Abeta-induced defects in axonal transport","volume":"330","author":"Vossel","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.03.001_bb0525","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.canlet.2016.03.045","article-title":"Challenges and opportunities for siRNA-based cancer treatment","volume":"387","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.nbd.2019.03.001_bb0530","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/187152709789541934","article-title":"RNAi for the treatment of prion disease: a window for intervention in neurodegeneration?","volume":"8","author":"White","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.nbd.2019.03.001_bb0535","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nbt1339","article-title":"Mechanisms and optimization of in vivo delivery of lipophilic siRNAs","volume":"25","author":"Wolfrum","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0540","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/jvi.50.3.691-697.1984","article-title":"Characterization of saturable binding sites for rabies virus","volume":"50","author":"Wunner","year":"1984","journal-title":"J. Virol."},{"key":"10.1016\/j.nbd.2019.03.001_bb0545","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1080\/15548627.2016.1214777","article-title":"Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats","volume":"12","author":"Xilouri","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.nbd.2019.03.001_bb0550","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/323738a0","article-title":"Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100","volume":"323","author":"Yang","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2019.03.001_bb0555","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1172\/JCI64502","article-title":"shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model","volume":"125","author":"Zharikov","year":"2015","journal-title":"J. Clin. Invest."}],"updated-by":[{"DOI":"10.1016\/j.nbd.2023.106397","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000}}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996119300609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996119300609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:15:33Z","timestamp":1760850933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996119300609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":111,"alternative-id":["S0969996119300609"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2019.03.001","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic peptide mediated delivery of an siRNA targeting \u03b1-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}